CD48 and Miyoshi myopathy: Given this broad expression of SLAMF2 in most MM patients, Lewis and colleagues evaluated the cytotoxic effect of SGN-CD48A, a CD48-targeting antibody–drug conjugate (ADC) with a glucuronide–monomethylauristatin E (MMAE) linker [51].